Indivior
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Virginia, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
10710 Midlothian Tpke Ste 125, Richmond,...Phone Number
(804) 379-1090Website
www.indivior.comRevenue
$1.3 BillionStock Symbol
INDVIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
7
6
1
2
2
2
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The companys product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company was incorporated in 2014 and is headquartered in Richmond,...Explore more
Indivior Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Indivior your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Indivior is spiking on competitors!
Check if Indivior has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Indivior had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Indivior has new funding data
Indivior, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Indivior recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Indivior
Product Launch: Get notified when Indivior launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Indivior
Compare insights from companies similar to Indivior, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Indivior
$1.3B
501-1,000
Public
-
1994
BC
Bal ChopraSegment Chief Financial Officer & Senior VP, Finance, Operations (US)
Company Profile Activity
Activity Insights
Indivior is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Indivior is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Indivior.
Indivior Tech Stack
A closer look at the technologies used by Indivior
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Open Position
Person-Based
Indivior News & Media
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide.New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of suIndivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:Indivior Announces $175 Million Accelerated Share Repurchase
RICHMOND, Va., May 04, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (“the ASR”) with Barclays Bank PLC (“Barclays”). The ASR will be executed under Indivior’s existing $400 million share repurchase program previously authorized by the Company’s Board of Directors. The ASR reflects the Company’s confidence in its long-term strategy, cash flow generation, and commitment to disc
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Indivior
Sign Up For FreeTo access detailed company insights
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The companys product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It markets and promotes SUBOXONE subli... Read More
